Q2 Financial Performance
Rhythm Pharmaceuticals has announced robust financial results for the second quarter of 2024, with revenues reaching $29.1 million, largely due to the success of their drug IMCIVREE, used for treating Bardet-Biedl syndrome (BBS).
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
